In general, ROCK2 appears to be an attractive target for the development of new therapeutic strategies, not only for NCL, but also in a wide range of more common neurodegenerative diseases to potentially halt or delay disease progression (Fig. 7D). The gene discussed is ROCK2; the disease is neurodegenerative disease.